Journal of the Korean Ophthalmological Society 1997;38(2):242-250.
Published online February 1, 1997.
Ganciclovir Treatment for Cytomegalovirus Retinitis in Renal Transplant Recipients.
I T Kim, J H Lim, H D Seo
Department of Ophthalmology, School of Medice, Kyungpook National University, Taegu, Korea.
신이식후 발생한 거대세포바이러스망막염에서 Ganciclovir 치료
김인택(In Taek Kim),임정훈(Jung Hun Lim),서형덕(Hyung Duck Seo)
Abstract
Two patients of cytomegalovirus(CMV) retinitis after renal transplantation were reviewed. And the clinical and virologic efficacy of ganciclovir in the treatment of severe CMV retinitis in renal transplant recipients was investigated. Diagnosis was based on the typical funduscopic appearance of CMV retinitis clinically, and the presence of CMV antibody IgG and IgM serologically. Two patients received ganciclovir intravenously at a dose of 100 to 600 mg/day for 46 to 52 days. Clinical stabilization or imporvement in the visual acuity and the lesion of retinitis ocurred in 2 patients within 1 month after the administration of ganciclovir. Mild or moderate decrease of white blood cell was the major side effect encountered during the administration of ganciclovir. By reducing the amount or stopping of ganciclovir, the number of the decreased white blood cell was increased rapidly above 2.000/mm^3 within 5 days. And none of these cases relapsed after the administration of ganciclovir for at least approximately 4 months. We conclude that ganciclovir treatment is clinically effective in improving CMV retinitis in renal transplant recipients.
Key Words: CMV retinitis;Ganciclovir;Renal transplantation


ABOUT
BROWSE ARTICLES
EDITORIAL POLICY
FOR CONTRIBUTORS
Editorial Office
SKY 1004 Building #701
50-1 Jungnim-ro, Jung-gu, Seoul 04508, Korea
Tel: +82-2-583-6520    Fax: +82-2-583-6521    E-mail: kos08@ophthalmology.org                

Copyright © 2024 by Korean Ophthalmological Society.

Developed in M2PI

Close layer
prev next